07/01/2014 current position Associate Medical Director Medical oncology 01/02/ /01/2014

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "giulia.pasello@ioveneto.it 07/01/2014 current position Associate Medical Director Medical oncology 01/02/2010 06/01/2014"

Transcription

1 Curriculum Vitae Europass Personal Information Surname(s) / Name(s) Address Via Gattamelata 64 Padova E mail Nationality Italian Date of birdth 17/10/1979 Gender Occupational Field Female Medical Oncology Work experience Dates Dates 07/01/2014 current position Associate Medical Director Clinical and research activity in thoracic oncology Second Medical Oncology Unit, Istituto Oncologico Veneto, Via Gattamelata 64, Padua (Italy) Medical Oncology 01/02/ /01/2014 Medical Oncologist (with contract) Clinical and research activity in thoracic oncology Second Medical Oncology Unit, Istituto Oncologico Veneto Via Gattamelata 64, Padua (Italy) Medical oncology Dates 01/07/ /12/2009 Fellow Basic research about malignant pleural mesothelioma Pagina 1 / 8 - Curriculum vitae di

2 Molecular Oncology laboratories, University of Zurich (Switzerland), Prof. Rolf Stahel Molecular Oncology Dates 01/07/ /12/2008 Resident in Medical Oncology Clinical management of oncological pediatric patients Pediatric oncohematology, University of Padua (Italy) Pediatric Oncology and Haematology Dates 01/07/ /12/2009 Resident in Medical Oncology Clinical management and research in Oncology Second Medical Oncology Unit, Istituto Oncologico Veneto Padua (Italy) Medical Oncology Dates 01/01/ /06/2007 Resident in Medical Oncology Basic and translational research in oncology Oncological and Surgical Science Department, Oncology Section, University of Padua (Italy) Molecular Oncology Education and Training Dates Title of qualification awarded Principal subjects/occupational skills covered 01/01/2012 currently ongoing PhD Neoangiogenic biomarkers and therapeutic targets in malignant pleural mesothelioma Dates 01/01/ /12/2010 Title of qualification awarded Principal subjects/occupational skills covered Name and type of organisation providing education and training Residency in Medical Oncology Medical Oncology Residency School in Medical Oncology (University of Padua) Pagina 2 / 8 - Curriculum vitae di

3 Padua (Italy) Dates 01/10/ /10/2005 Title of qualification awarded Name and type of organisation providing education and training Other training experiences Graduation in medicine and surgery University of Ferrara (Ferrara, Italy) March 2014: admitted at the 13th ESO ESMO Masterclass in Clinical Oncology where she attended plenary lectures regarding state of the art clinical evaluation and treatments in oncology. As a selected participant the applicant presented a research abstract which was selected for publication and had the opportunity to present and discuss with the faculty clinical cases of thoracic cancer. Personal skills and competences Mother tongue(s) Other language(s) Italian English: excellent reading, writing, speaking Organisational skills and competences Clinical and translational research projects design and conduction. Additional informations : recipient of ESMO (European Society for Medical Oncology) translational research fellowship award 2012: recipient of IMIG (International Mesothelioma Interest group) travel award 2014 Saro Leggio award for translational study of malignant pleural mesothelioma 2011 current position: National AIOM (Assicioazione Italiana di Oncologia Medica) young working group elected member Since January 2014 she is lecturer at the fith year of Specialization School of Medical Oncology with the Pagina 3 / 8 - Curriculum vitae di

4 teaching Epidemiology, diagnosis and staging of neuroendocrine tumors, and supervisor of several students attending the Specialization School in Medical Oncology List of publications PUBLICATION IN PEER REVIEWED JOURNALS WITH IMPACT FACTOR 1) Pasello G, Agata S, Bonaldi L, Corradin A, Montagna M, Zamarchi R, Parenti A, Cagol M, Zaninotto G, Ruol A, Ancona E, Amadori A and Saggioro D. DNA copy number alterations correlate with survival of oesophageal adenocarcinoma patients. Modern Patology, 2009;22 (1): ) Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C. Second and third line treatment in non small cell lung cancer. Crit Rev Oncol Hematol, 2009; 71 (2): ) Favaretto A, Pasello G, Loreggian L, Breda C, Braccioni F, Marulli G, Stragliotto S, Magro C, Sotti G, Rea F. Preoperative concomitant chemo radiotherapy (CT RT) in Superior Sulcus Tumor (SST): a monoinstitutional experience. Lung Cancer, 2010 May; 68(2): ) Pasello G and Favaretto A. Molecular targets in malignant pleural mesotelioma treatment. Current Drug Targets, 2009; 10: ) Sidi R*, Pasello G*, Opitz I, Soltermann A, Tutic M, Rehrauer H, Weder W, Stahel RA, Felley Bosco E. *Equal contributors Induction of senescence markers after neo adjuvant chemotherapy of malignant pleural mesothelioma and Pagina 4 / 8 - Curriculum vitae di

5 association with clinical outcome: An exploratory analysis. Eur J Cancer, 2011; 47 (2): ) Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F and Favaretto A. Prognostic and Predictive Implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Research 2010; 30: ) Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M & Ciardiello F. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non small cell lung cancer: a randomized phase II study Annals of Oncology, 2011; 22 (7): ) Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A. Platinum based doublet chemotherapy in pre treated malignant pleural mesothelioma (MPM) patients: A mono institutional experience Lung Cancer, 2011;73: ) Rumiato E, Pasello G, Montagna M, Scaini MC, De Salvo GL, Parenti A, Cagol M, Ruol A, Ancona E, Amadori A, Saggioro D. DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. Cancer Letters, 2011; 310 (1): ) Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, Pagina 5 / 8 - Curriculum vitae di

6 De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G STEP Investigators Phase I II trial of gemcitabine based first line chemotherapies for small cell lung cancer in elderly patients with performance status 0 2: the G STEP trial J Thorac Oncol Jan;7(1): ) Pasello G, Ceresoli GL, Favaretto A An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesotelioma. Cancer Treat Rev Feb;39 (1): ) Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first line erlotinib followed by second line cisplatin/gemcitabine chemotherapy in advanced nonsmall cell lung cancer. J Thorac Oncol Dec;7 (12): ) Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM) Anticancer Res Dec;32 (12): ) Marulli G, Di Chiara F, Braccioni F, Perissinotto E, Pasello G, Gino Favaretto A, Breda C, Rea F. Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma Eur J Cardiothorac Surg Jul; 44 (1): Pagina 6 / 8 - Curriculum vitae di

7 15) Pasello G, Urso L, Conte P, Favaretto A. Effects of Sulfonylureas on Tumor Growth: A Review of the Literature. The Oncologist 2013, 18(10): ) Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer Jul 15;111(2): doi: /bjc Epub 2014 Jun ) Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L, Perissinotto E, Romanello P, Favaretto AG, Pasello G, Rea F. Outcomes and prognostic factors of non smallcell lung cancer with lymph node involvement treated with induction treatment and surgical resection. Interact Cardiovasc Thorac Surg Aug;19(2):256 62; discussion 262. doi: /icvts/ivu141. Epub 2014 May 13 18) Pasello G, Urso L, Silic Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A. Synergistic antitumor activity of recombinant human Apo2L/TRAIL in combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma. J Thorac Oncol 2014, 2014 Jul;9(7): ) Schiavon M, Marulli G, Nannini N, Pasello G, Lunardi F, Balestro E, Perissinotto E, Rebusso A, Saetta M, Rea F, Calabrese F. COPD related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. Lung Cancer Dec;86(3): PUBLICATION IN PEER REVIEWED JOURNALS Pagina 7 / 8 - Curriculum vitae di

8 WITHOUT IMPACT FACTOR 1) Favaretto AG, Pasello G, and Magro C Second and third line treatment in advanced nonsmall cell lung cancer. Discovery Medicine, 2009; 8 (43): ) Pasello G, Altavilla G, Bonanno L, Rea F, Favaretto A. A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: a case report. J Thorac Disease 2010; 2: BOOK CHAPTER - Giulia Pasello and Adolfo Favaretto. Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma. Malignant Mesothelioma Chapter 5 December Giovanni Luca Ceresoli, Giulia Pasello, Fiorella Calabrese. ESMO book: Thoracic Tumours Essentials for Clinicians: Malignant Pleural Mesothelioma March Participation as a speaker and scientiific committee to several national conferences - Reviewer of Journal of thoracic disease - Member of ASCO since 2008; member of ESMO and AIOM since 2009 PADOVA, 12/mar/2015 Pagina 8 / 8 - Curriculum vitae di

laura.bonanno@ioveneto.it Medical Oncology 2 Unit. Medical Oncology 2 Istituto Oncologico Veneto I.R.C.C.S

laura.bonanno@ioveneto.it Medical Oncology 2 Unit. Medical Oncology 2 Istituto Oncologico Veneto I.R.C.C.S E UROPEAN C URRICULUM V ITAE PERSONAL DATA Name Laura Bonanno Work address Medical Oncology 2 I.O.V. Istituto Oncologico Veneto I.R.C.C.S. Via Gattamelata, 64 35128 Padova (IT) Telefono +390498215553/5931

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

E UROPEAN CURRICULUM VITAE FORMAT

E UROPEAN CURRICULUM VITAE FORMAT E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto

More information

Total IF: 383.368 (2011 Journal of Citation Report Institute of Scientific Information) Total H Index : 16 (Harzing s index 2011)

Total IF: 383.368 (2011 Journal of Citation Report Institute of Scientific Information) Total H Index : 16 (Harzing s index 2011) Dr. Adolfo Favaretto LIST of publications with IF Total IF: 383.368 (2011 Journal of Citation Report Institute of Scientific Information) Total H Index : 16 (Harzing s index 2011) JOURNAL IF Publications

More information

CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany

CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

ESMO Translational Research Fellowship

ESMO Translational Research Fellowship ESMO Translational Research Fellowship Identification of novel molecular targets and biological agents for the chemotherapy of malignant pleural mesothelioma Giulia Pasello (July 2010 July 2012) Final

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?

Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy? JBUON 2015; 20(2): 376-380 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy,

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma

Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma Chapter 5 Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma Giulia Pasello and Adolfo Favaretto Additional information is available at the end of the chapter http://dx.doi.org/10.5772/47880 1.

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Moving forward, where are we with Clinical Trials?

Moving forward, where are we with Clinical Trials? Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10 Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the

More information

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience Bearz et al. BMC Research Notes 2012, 5:482 RESEARCH ARTICLE Open Access Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience Alessandra Bearz 1,9*, Renato Talamini 2,

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma

More information

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating?

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating? Dr Peter Briggs Medical Oncologist Lung Cancer & Mesothelioma: is it worth treating? GOALS OF CANCER THERAPY CURE Good chance Medium chance Low chance PALLIATION Life prolonging Symptomatic improvement

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Update on Clinical Trials and Foundation Funded Grants

Update on Clinical Trials and Foundation Funded Grants Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control

More information

ETOP European Thoracic Oncology Platform c/o IBCSG Effingerstrasse 40 3008 Bern. Phone +41 31 389 93 91 Fax +41 31 389 92 35. www.etop-eu.

ETOP European Thoracic Oncology Platform c/o IBCSG Effingerstrasse 40 3008 Bern. Phone +41 31 389 93 91 Fax +41 31 389 92 35. www.etop-eu. Annual Report 2012 ETOP European Thoracic Oncology Platform c/o IBCSG Effingerstrasse 40 3008 Bern Phone +41 31 389 93 91 Fax +41 31 389 92 35 www.etop-eu.org UBS AG Postfach CH-8098 Zürich Switzerland

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Featured Article Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Valerie W. Rusch 1, Dorothy Giroux 2 1 Memorial Sloan-Kettering Cancer Center, New

More information

Special Training Three months training on general thoracic surgery at Emory University,Atlanta, Georgia, USA in

Special Training Three months training on general thoracic surgery at Emory University,Atlanta, Georgia, USA in NCI, Kasr El Elini St. Fom El Khalig, Cairo Egypt Mobile : +20100-104 1988 Clinic : +2 239 3 5544 Voice : +2 28406421 Abdelrahman.mohamed@nci.cu.edu.eg Email : rahmannci@yahoo.com Abdel Rahman Mohammed

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic

More information

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer

More information

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment March 2014 KOL Insight: Non-small cell lung cancer A FirstWord Therapy Trends Report KOL Insight: Lung Cancer Published March 2014 Copyright 2014 Doctor s Guide Publishing Limited All rights reserved.

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Italian clinical research in non-small-cell lung cancer

Italian clinical research in non-small-cell lung cancer Annals of Oncology 16 (Supplement 4): iv110 iv115, 2005 doi:10.1093/annonc/mdi919 Italian clinical research in non-small-cell lung cancer C. Gridelli 1, A. Rossi 1, D. Galetta 2, P. Maione 1, C. Ferrara

More information

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010 Lung Cancer Network Group Lung Cancer Awareness Month November 2010 Lung cancer is the leading cause of cancer related death in the Northern Ireland and the UK 1,2. Each year in Northern Ireland approximately

More information

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? 4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Probe: Could you tell me about when?

Probe: Could you tell me about when? PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

1 of 6 6/1/13 6:49 PM

1 of 6 6/1/13 6:49 PM A service of the U.S. National Institutes of Health Trial record 7 of 203 for: Melanoma Analysis Previous Study Return to List Next Study Expression Analysis of Specific Markers in Non-small Cell Lung

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Alimta (pemetrexed) Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011

More information

Non-Small Cell Lung Cancer Therapies

Non-Small Cell Lung Cancer Therapies Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome

More information

Update on Small Cell Lung Cancer

Update on Small Cell Lung Cancer Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics

Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics Edoardo Colzani, M.D., M.P.H. Department of Medical Epidemiology and Biostatistics

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team Project Name: Peer Review Date: 26/05/2014 Release: FINAL Author: Owner: Client: Document Number: Timothy Jackson Cancer Information

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

PET Scanning and Lung Cancer- A Surgeon s Perspective

PET Scanning and Lung Cancer- A Surgeon s Perspective PET Scanning and Lung Cancer- A Surgeon s Perspective Disclaimer Member of advisory board Pfizer Changing Environment Incidence Biology Detection Technology/treatment options Canadian Cancer Statistics

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales

Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales Eur Respir J 1997; 10: 1552 1558 DOI: 10.1183/09031936.97.10071552 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Survey on the treatment

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

Please see the LUCADA data manual v3.1.3, available in the downloads section

Please see the LUCADA data manual v3.1.3, available in the downloads section National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands

More information

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE 2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE Please fill your post-test answers in on this page and fax it back to the ATS Education Unit, ATTN: Elizabeth

More information